Selected research
Industry Research
Somatostatin Analogs Industry Research Report 2026
Market perspective
The global Somatostatin Analogs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Somatostatin Analogs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Somatostatin Analogs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Somatostatin Analogs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Somatostatin Analogs include Novartis, Peptron, Ipsen Biopharmaceutical and Chiasma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Somatostatin Analogs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Somatostatin Analogs Market by Company
Novartis
Peptron
Ipsen Biopharmaceutical
Chiasma
Somatostatin Analogs Segment by Type
Pasireotide
Lanreotide
Octreotide
Somatostatin Analogs Segment by Application
Acromegaly
Neuroendocrine Tumor
Cushing Syndrome
Carcinoid Syndrome
Others
Somatostatin Analogs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Somatostatin Analogs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Somatostatin Analogs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Somatostatin Analogs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Somatostatin Analogs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Somatostatin Analogs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Somatostatin Analogs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pasireotide
- Lanreotide
- Octreotide
Applications
- Acromegaly
- Neuroendocrine Tumor
- Cushing Syndrome
- Carcinoid Syndrome
- Others
Companies covered
- Novartis
- Peptron
- Ipsen Biopharmaceutical
- Chiasma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Somatostatin Analogs Market Size (2021-2032)
- 2.2.2 Global Somatostatin Analogs Sales (2021-2032)
- 2.2.3 Global Somatostatin Analogs Market Average Price (2021-2032)
- 2.3 Somatostatin Analogs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Pasireotide
- 2.3.3 Lanreotide
- 2.3.4 Octreotide
- 2.4 Somatostatin Analogs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Acromegaly
- 2.4.3 Neuroendocrine Tumor
- 2.4.4 Cushing Syndrome
- 2.4.5 Carcinoid Syndrome
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Somatostatin Analogs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Somatostatin Analogs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Somatostatin Analogs Revenue of Manufacturers (2021-2026)
- 3.4 Global Somatostatin Analogs Average Price by Manufacturers (2021-2026)
- 3.5 Global Somatostatin Analogs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Somatostatin Analogs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Somatostatin Analogs, Product Type & Application
- 3.8 Global Manufacturers of Somatostatin Analogs, Established Date
- 3.9 Global Somatostatin Analogs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis Somatostatin Analogs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis Somatostatin Analogs Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 Peptron
- 4.2.1 Peptron Company Information
- 4.2.2 Peptron Business Overview
- 4.2.3 Peptron Somatostatin Analogs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Peptron Somatostatin Analogs Product Portfolio
- 4.2.5 Peptron Recent Developments
- 4.3 Ipsen Biopharmaceutical
- 4.3.1 Ipsen Biopharmaceutical Company Information
- 4.3.2 Ipsen Biopharmaceutical Business Overview
- 4.3.3 Ipsen Biopharmaceutical Somatostatin Analogs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Ipsen Biopharmaceutical Somatostatin Analogs Product Portfolio
- 4.3.5 Ipsen Biopharmaceutical Recent Developments
- 4.4 Chiasma
- 4.4.1 Chiasma Company Information
- 4.4.2 Chiasma Business Overview
- 4.4.3 Chiasma Somatostatin Analogs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Chiasma Somatostatin Analogs Product Portfolio
- 4.4.5 Chiasma Recent Developments
5 Global Somatostatin Analogs Market Scenario by Region
- 5.1 Global Somatostatin Analogs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Somatostatin Analogs Sales by Region: 2021-2032
- 5.2.1 Global Somatostatin Analogs Sales by Region: 2021-2026
- 5.2.2 Global Somatostatin Analogs Sales by Region: 2027-2032
- 5.3 Global Somatostatin Analogs Revenue by Region: 2021-2032
- 5.3.1 Global Somatostatin Analogs Revenue by Region: 2021-2026
- 5.3.2 Global Somatostatin Analogs Revenue by Region: 2027-2032
- 5.4 North America Somatostatin Analogs Market Facts & Figures by Country
- 5.4.1 North America Somatostatin Analogs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Somatostatin Analogs Sales by Country (2021-2032)
- 5.4.3 North America Somatostatin Analogs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Somatostatin Analogs Market Facts & Figures by Country
- 5.5.1 Europe Somatostatin Analogs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Somatostatin Analogs Sales by Country (2021-2032)
- 5.5.3 Europe Somatostatin Analogs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Somatostatin Analogs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Somatostatin Analogs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Somatostatin Analogs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Somatostatin Analogs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Somatostatin Analogs Market Facts & Figures by Country
- 5.7.1 South America Somatostatin Analogs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Somatostatin Analogs Sales by Country (2021-2032)
- 5.7.3 South America Somatostatin Analogs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Somatostatin Analogs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Somatostatin Analogs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Somatostatin Analogs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Somatostatin Analogs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Somatostatin Analogs Sales by Type (2021-2032)
- 6.1.1 Global Somatostatin Analogs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Somatostatin Analogs Sales Market Share by Type (2021-2032)
- 6.2 Global Somatostatin Analogs Revenue by Type (2021-2032)
- 6.2.1 Global Somatostatin Analogs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Somatostatin Analogs Revenue Market Share by Type (2021-2032)
- 6.3 Global Somatostatin Analogs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Somatostatin Analogs Sales by Application (2021-2032)
- 7.1.1 Global Somatostatin Analogs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Somatostatin Analogs Sales Market Share by Application (2021-2032)
- 7.2 Global Somatostatin Analogs Revenue by Application (2021-2032)
- 7.2.1 Global Somatostatin Analogs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Somatostatin Analogs Revenue Market Share by Application (2021-2032)
- 7.3 Global Somatostatin Analogs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Somatostatin Analogs Value Chain Analysis
- 8.1.1 Somatostatin Analogs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Somatostatin Analogs Production Mode & Process
- 8.2 Somatostatin Analogs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Somatostatin Analogs Distributors
- 8.2.3 Somatostatin Analogs Customers
9 Global Somatostatin Analogs Analyzing Market Dynamics
- 9.1 Somatostatin Analogs Industry Trends
- 9.2 Somatostatin Analogs Industry Drivers
- 9.3 Somatostatin Analogs Industry Opportunities and Challenges
- 9.4 Somatostatin Analogs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst